A Phase 2 Trial to Evaluate SP-420 in Parkinson's Patients
Latest Information Update: 14 Dec 2020
Price :
$35 *
At a glance
- Drugs SP 420 (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Abfero Pharmaceuticals
- 14 Dec 2020 New trial record